SB225002 is a potent and selective non-peptide inhibitor of CXCR2 with IC50 of 22 nM, showing > 150-fold selectivity over CXCR1 and four other 7-TMRs.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | CXCR1 ↓ ↑ | CXCR2 ↓ ↑ | CXCR4 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Reparixin | ✔ | 99%+ | |||||||||||||||||
SB225002 |
+++
CXCR2, IC50: 22 nM |
99%+ | |||||||||||||||||
Plerixafor |
++
CXCR4, IC50: 44 nM |
99% | |||||||||||||||||
AMD 3465 6HBr | ✔ | 98% | |||||||||||||||||
WZ811 |
++++
CXCR4, EC50: 0.3 nM |
98% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | CXCR2 is expressed in human neutrophilsand a subset of T-cells, which can mediate neutrophil migration to sites of inflammation through binding with and internalization through its ligand IL-8 or related chemokines containing a common amino-terminal ELR amino acid sequence (Glu-Leu-Arg), such as GROα, GROβ, GROγ, NAP-2 and ENA-78. SB 225002 is a non-peptide, potent and selective CXCR2 inhibitor with IC50 value of 22 nM, >150-fold selectivity over CXCR1 and four other 7-TMRs tested. SB-225002 can produce a dose-dependent inhibition of calcium mobilization induced by IL-8 and GROα with IC50 values of 8 nM and 10 nM, respectively, in differentiated HL60 cells with predominantly express CXCR2 (80%) with a much smaller number of CXCR1 (20%) receptors, as well as inhibit both IL-8 (1nM)- and GROα (10nM)-mediated human neutrophil chemotaxis with IC50s of 20 nM and 60 nM, respectively. This effect of SB-225002 on chemotaxis can also be observed in in vivo study[1]. Daily intraperitoneal injection with SB225002 at dose of 5 mg/kg for 4 weeks showed significantly tumor growth inhibition by ~45% decrease in tumor size of LLC tumor bearing GRK6-/- mice. |
作用机制 | SB-225002 can inhibit CXCR2 through competition with IL-8.[1] |
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
CHO cells | Function assay | Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells, IC50=22 nM | 17236763 | ||
HEK293 cells | Function assay | Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assay, IC50=40 nM | 25254640 | ||
human PMNs | Function assay | Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay, IC50=30 nM | 25254640 |
Dose | Mice: 0.3 mg/kg - 1 mg/kg[3] (i.p.), 4 mg/kg[4] (i.p.) |
Administration | i.p. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.84mL 0.57mL 0.28mL |
14.20mL 2.84mL 1.42mL |
28.40mL 5.68mL 2.84mL |
CAS号 | 182498-32-4 |
分子式 | C13H10BrN3O4 |
分子量 | 352.14 |
别名 | |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Inert atmosphere,Store in freezer, under -20°C |
溶解度 |
DMSO: 105 mg/mL(298.18 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |
IP 2% DMSO+2% Tween80+35% PEG300+water 2.5 mg/mL clear PO 0.5% CMC-Na 41 mg/mL suspension |